Rantes Mouse
Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
Description
Rantes Mouse Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 68 amino acids and having a molecular mass of 7876 Dalton.
The Mouse Rantes is purified by proprietary chromatographic techniques.
Product Specs
Recombinant Mouse Rantes, expressed in E.Coli, is a non-glycosylated polypeptide chain consisting of 68 amino acids. With a molecular weight of 7876 Daltons, it is purified using proprietary chromatographic techniques.
Lyophilized from a concentrated (1mg/ml) solution in water, without any additives.
For reconstitution, it is advised to dissolve the lyophilized Rantes in sterile 18MΩ-cm H₂O at a minimum concentration of 100µg/ml. This solution can be further diluted in other aqueous solutions as needed.
Purity exceeds 95.0% as determined by: (a) Reverse Phase High Performance Liquid Chromatography (RP-HPLC) analysis. (b) SDS-PAGE analysis.
The biological activity of the recombinant Mouse Rantes is evaluated based on its ability to chemoattract human lymphocytes and murine T-cells. This chemotactic activity is observed at concentrations ranging from 1 to 10 ng/ml.
Product Science Overview
The recombinant mouse CCL5/RANTES protein is typically derived from E. coli and consists of amino acids Ser24 to Ser91 . The molecular mass of this protein is approximately 7.8 kDa . It is often produced in a carrier-free form to avoid interference from other proteins such as Bovine Serum Albumin (BSA) .
CCL5/RANTES is primarily involved in the inflammatory immune response. It achieves this by attracting and activating leukocytes, including T cells, eosinophils, and basophils . This chemokine is known for its ability to direct the migration of these immune cells to sites of inflammation or infection .
Increased expression of CCL5 has been associated with various inflammatory disorders and pathologies. For instance, it is highly expressed in breast tumor cells and is linked to tumor progression by recruiting monocytes into tumor sites . Additionally, CCL5 has been shown to have pro-angiogenic effects, promoting the formation of new blood vessels through its interaction with receptors CCR1 and CCR5 .
CCL5 also plays a protective role against viral infections, including influenza, RSV, HCMV, HCV, and HIV. It can inhibit HIV infection by competing with the virus for CCR5 binding . Moreover, CCL5 has been implicated in the development of asthma, atherosclerosis, and fibrosis .
